KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Non-Current Deffered Revenue (2018 - 2025)

Vir Biotechnology (VIR) has disclosed Non-Current Deffered Revenue for 8 consecutive years, with $9.4 million as the latest value for Q3 2025.

  • Quarterly Non-Current Deffered Revenue changed N/A to $9.4 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $9.4 million through Sep 2025, changed N/A year-over-year, with the annual reading at $1.5 million for FY2023, 97.13% down from the prior year.
  • Non-Current Deffered Revenue hit $9.4 million in Q3 2025 for Vir Biotechnology, up from $1.5 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $55.5 million in Q2 2021 to a low of $1.5 million in Q4 2023.
  • Historically, Non-Current Deffered Revenue has averaged $25.5 million across 5 years, with a median of $7.6 million in 2022.
  • Biggest five-year swings in Non-Current Deffered Revenue: skyrocketed 1354.68% in 2021 and later tumbled 97.13% in 2023.
  • Year by year, Non-Current Deffered Revenue stood at $3.8 million in 2021, then soared by 1294.68% to $53.2 million in 2022, then crashed by 97.13% to $1.5 million in 2023, then changed by 0.0% to $1.5 million in 2024, then soared by 518.15% to $9.4 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for VIR at $9.4 million in Q3 2025, $1.5 million in Q1 2024, and $1.5 million in Q4 2023.